Samy Zaky, Mohamed El Badry, Hoda A Makhlouf, Sherief M Abd-Elsalam, Tarik S Sarhan, Noha H Eltaweel, Heba Aly, Akram Abdelbary, Ahmed Said, Mohammed Hamdy Farouk, Amin Abdelbaki, Hanaa Fathelbab, Reham Hammad, Fathiya El-Raey
SARS-CoV-2 causes mostly mild cases. However, a considerable number of patients develop fatal acute respiratory distress syndrome due to the cytokine storm and imbalanced immune response. Several therapies depending on immunomodulation have been used, including glucocorticoids and IL-6 blockers. However, their efficacy is not perfect with all patients and patients with concomitant bacterial infections and sepsis. Accordingly, studies on different immunomodulators, including extracorporeal techniques, are crucial to save this category of patients...
May 2, 2023: Infectious Disorders Drug Targets